ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeSocazolimab, in combination with chemotherapy, has been shown to prolong progression-free survival (PFS) and overall survival (OS) compared with chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). This study is the first to evaluate its cost-effectiveness from the perspectives of both the U.S. payer and Chinese healthcare systems.
methodsA Markov state-transition model was employed to conduct an economic evaluation, incorporating clinical and economic parameters from both the U.S. and China. Baseline patient characteristics and key clinical inputs were sourced from a randomized phase 3 trial, whereas cost and utility values were derived from open-access databases and published literature. The primary outcomes assessed included quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB). Model uncertainty was addressed through probabilistic sensitivity, one-way sensitivity, and scenario analyses.
resultsIn the base-case scenario, the addition of socazolimab to chemotherapy resulted in a marginal QALY gain of 0.09, at an incremental cost of $14,504.53, leading to an ICER of $152,228.60 per QALY. This ICER was below China's willingness-to-pay (WTP) threshold of $40,354.27 per QALY, making it not cost-effective, with an INHB of -0.26 QALYs and an INMB of -$10,523.93. In the U.S., while the incremental QALY gain remained at 0.10, the additional cost increased to $85,599.55, yielding an ICER of $878,912.80 per QALY, far exceeding that of the U.S. WTP threshold of $150,000.00, confirming its lack of cost-effectiveness.
conclusionsThe combination of socazolimab with chemotherapy is not a cost-effective first-line treatment option for ES-SCLC in either China or the United States, highlighting the need for price adjustments and alternative treatment strategies to improve economic viability.
Indexed as
Identifiers
40841504What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.